In a significant development, Modalis Therapeutics has received a coveted paediatric disease designation from the US Food and Drug Administration for their innovative work in epigenome editing. This breakthrough technology holds the promise of revolutionizing the treatment of various genetic disorders by modifying gene expression at the epigenetic level. Epigenome editing involves precise modifications to […]